ClinicalTrials.Veeva

Menu
C

Center for Emotional Fitness | Cherry Hill, NJ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dasotraline
SPD489
BI 1358894
Cariprazine
Troriluzole
Lisdexamfetamine dimesylate
Rapastinel
Brexpiprazole
Azetukalner
OPC-34712

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 64 total trials

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) (X-CEED)

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo
Drug: Azetukalner

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Azetukalner
Drug: Placebo

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Active, not recruiting
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: SEP-363856

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Active, not recruiting
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000
Locations recently updated

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Enrolling
Major Depressive Disorder (MDD)
Drug: Ropanicant
Drug: Placebo

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

Otsuka logo
Sumitomo Pharma logo
Shire logo
Pfizer logo
Boehringer Ingelheim logo
Biohaven logo
Indivior logo
Allergan logo
AbbVie logo
Biohaven logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems